Determination of regional cerebral function with FDG-PET imaging in neuropsychiatric disorders

Seminars in Nuclear Medicine

Volumn 32, Issue 1, 2002, Pages 13-34

  Newberg, Andrew ^a   Alavi, Abass ^a   Reivich, Martin ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFFECTIVE NEUROSIS; ALCOHOLISM; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; BRAIN TUMOR; CEREBROVASCULAR DISEASE; COCAINE DEPENDENCE; DYSTONIA; EPILEPSY; HEAD INJURY; HUMAN; HUNTINGTON CHOREA; MENTAL DISEASE; NEUROLOGIC DISEASE; NIEMANN PICK DISEASE; OBSESSION; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIMARY PROGRESSIVE APHASIA; PROGRESSIVE SUPRANUCLEAR PALSY; SCHIZOPHRENIA; SEIZURE;

EID: 0036154093     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2002.29276     Document Type: Article

References (341)

1. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man
2. Assessment: Positron emission tomography
3. Positron emission tomography as a diagnostic tool: A reassessment based on literature review
4. Future developments in positron-emission tomography for incorporation into the clinical sphere
5. Image separation of radioisotope scanning
6. The MARK IV system for radionuclide computed tomography of the brain
7. Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography. Evolution over the past 2 decades
8. Three-dimensional imaging characteristics of the HEAD PENN-PET scanner
9. Labeled 2-deoxyglucose analogs, 18F-labeled 2-deoxyglucose-2-fluoro-D-glucose, 2-deoxy-2-fluoro-D-manose and 14C-2-deoxy-2-fluoro-D-glucose
10. A positron emission transaxial tomography for nuclear medicine imaging (PET)
11. Design considerations for a positron emission transaxial tomo-graph (PET-III)
12. Normal and pathological aging - Findings of positron-emission-tomography
13. The metabolic topography of normal aging
14. Positron emission tomography in aging and dementia: Effect of cerebral atrophy
15. Effects of human aging on patterns of local cerebral glucose utilization determined by the (18F) fluorodeoxyglucose method
16. Positron emission tomography studies of normal aging, a replication of PET III and 18-FDG using PET IV and II-CDG
17. Effects of normal aging on whole brain and regional glucose metabolism as assessed by F-18 positron emission tomography
18. Reduced temporal lobe glucose metabolism in aging
19. Sex differences in human brain morphometry and metabolism: An in vivo quantitative magnetic resonance imaging and positron emission tomography study on the effect of aging
20. Age-related differences in neural activity during item and temporal-order memory retrieval: A positron emission tomography study
21. Age differences in the frontal lateralization of verbal and spatial working memory revealed by PET
22. Age-related differences in neural activity during memory encoding and retrieval: A positron emission tomography study
23. Corticolimbic interactions associated with performance on a short-term memory task are modified by age
24. Effects of age on brain activation during auditory-cued thumb-to-index opposition: A positron emission tomography study
25. Age-related differences in visual perception: A PET study
26. Recruitment of unique neural systems to support visual memory in normal aging
27. Age-related changes in regional cerebral blood flow during working memory for faces
28. Adult age differences in the functional neuroanatomy of verbal recognition memory
29. Age-related shift in brain region activity during successful memory performance
30. Sensitivity of cerebral glucose metabolism to age, gender, brain volume, brain atrophy, and cerebrovascular risk factors
31. Controlling for cerebral atrophy in positron emission tomography data
32. Quantitative analysis of PET and MRI data in normal aging and Alzheimer's disease: Atrophy weighted total brain metabolism and absolute whole brain metabolism as reliable discriminators
33. Relation of measured brain glucose utilization and cerebral atrophy in man
34. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease
35. The NINCDS-ADRDA Workgroup criteria for the clinical diagnosis of probable Alzheimer's disease. A clinical pathological study of 57 cases
36. Clinical diagnosed Alzheimer's disease. Autopsy results in 150 cases
37. Cerebral function in aging and Alzheimer's disease. The role of PET
38. PET: Studies in dementia
39. Heterogeneous anterior-posterior metabolic patterns in dementia of the Alzheimer type
40. Relatons of EEG alpha background to parietal lobe function in Alzheimer's disease as measured by positron emission tomography and psychometry
41. Regional cerebral glucose metabolism in aging and senile dementia as determined by 18F-deoxyglucose and positron emission tomography
42. Positron emission tomography in the differential diagnosis of organic dementias
43. The effect of disease severity on local cerebral glucose metabolism in Alzheimer's disease
44. High-resolution PET studies in Alzheimer's disease
45. Positron emission tomography in neuropsychiatry
46. Single photon tomography in Alzheimer's disease and the dementias
47. Family history of dementia and regional cerebral glucose utilization (rCMRgle) in dementia of the Alzheimer type (AD)
48. Abnormal brain glucose metabolism in Alzheimer's disease as measured by positron emission tomography
49. Difference of regional cerebral metabolic pattern between presentile and senile dementia of the Alzheimer type: A factor analytic study
50. Cerebral metabolic patterns before the diagnosis of probable Alzheimer's disease
51. Comparison of PET, MRI and CT with pathology in a proven case of Alzheimer's disease
52. Brain metabolism as measured with positron emission tomography. Serial assessment in a patient with familial Alzheimer's disease
53. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron emission tomography
54. Focal cerebral glucose hypometabolism in definite Alzheimer's disease
55. The use of positron emission tomography in the clinical assessment of dementia
56. A comparison of FDG PET and MRI data from patients with atypical dementias and Alzheimer's disease (AD)
57. Comparison of FDG PET and levels of Tau protein in the diagnosis of patients with dementia
58. Early diagnosis of Alzheimer disease with positron emission tomography
59. The ratio of mesial to neocortical temporal lobe blood flow as a predictor of dementia
60. Positron emission tomography in familial Alzheimer disease
61. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E
62. Lack of association of apolipoprotein E epsilon 4 allele dose with cerebral glucose metabolism in Alzheimer disease
63. No difference in cerebral glucose metabolism in patients with Alzheimer disease and differing apolipoprotein E genotypes
64. The metabolic imaging severity rating scale (MISRS) in Alzheimer's disease: Comparison with quantitative data
65. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease
66. Cerebellar glucose consumption in normal and pathologic states using fluorine-FDG and PET
67. Regional cortical dysfunction in Alzheimer's disease as determined by positron emission tomography
68. Relationship between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease
69. 18-Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases
70. Stability of metabolic and neuropsychological asymmetries in dementia of the Alzheimer type
71. Anatomic and functional changes of the brain in normal aging and dementia as demonstrated by MRI, CT, and PET
72. Differences in lateral hemispheric asymmetries of glucose utilization between early- and late-onset Alzheimer type dementia
73. Region-specific corpus callosum atrophy correlates with the regional pattern of cortical glucose metabolism in Alzheimer disease
74. Comparison of CT, MR and PET in Alzheimer's dementia and normal aging
75. Neocortical metabolic abnormalities precede nonmemory cognitive defects in early Alzheimer's-type dementia
76. Analysis of brain and cerebrospinal fluid volumes with MR imaging. Impact on PET data, correction for atrophy
77. The effect of focal cerebral atrophy in positron emission tomographic studies of aging and dementia
78. Positron emission tomography metabolic data corrected for cortical atrophy using magnetic resonance imaging
79. Is absolute whole brain glucose metabolism a sensitive marker for Alzheimer's disease?
80. Metabolic imaging severity rating scale (MISRS) for the assessment of cerebral dysfunction in Alzheimer's disease
81. Slowly progressive aphasia without generalized dementia
82. Progressive aphasia "without dementia:" Evidence of more widespread involvement
83. An early description of slowly progressive aphasia
84. The naming disorder of dementia of Alzheimer type
85. Progressive aphasia without dementia: Further documentation
86. Slowly progressive aphasia without generalized dementia: Studies with positron emission tomography
87. Heterogeneity in progressive aphasia due to focal cortical atrophy
88. Primary progressive aphasia presenting as conduction aphasia
89. Slowly progressive aphasia: Three cases with language, memory, CT and PET data
90. Quantitative PET and MRI analysis in patients with primary progressive aphasia (PPA)
91. Positron emission tomography and histopathology in Pick's disease
92. Positron emission tomography and histopathology in Pick's disease
93. Positron emission tomography in Alzheimer's and Pick's disease
94. Cognitive, neuroimaging, and pathological studies in a patient with Pick's disease
95. Local cerebral glucose utilization in treated and untreated patients with Parkinson's disease
96. The metabolic anatomy of Parkinson's disease. Complementary (18F) fluorodeoxyglucose and (18F) fluorodopa positron emission tomographic studies
97. Cerebral glucose metabolism in Parkinson's disease
98. Positron emission tomography in Parkinson's disease. Glucose and dopa metabolism
99. Patterns of local cerebral glucose utilization determined in Parkinson's disease by the (18F) fluorodeoxyglucose method
100. Patterns of cerebral glucose utilization in Parkinson's disease and Huntington's disease
101. Positron emission tomography in hemiparkinsonism-hemiatrophy syndrome
102. Asymmetry of basal ganglia glucose metabolism and dopa responsiveness in parkinsonism
103. Levodopa-reduced glucose metabolism in striatopallidothalamocortico circuit in Parkinson's disease
104. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine
105. Movement disorders
106. Cortical glucose metabolism in Parkinson's and Alzheimer's disease
107. Similarities of cerebral glucose metabolism in Alzheimer's and Parkinsonian dementia
108. Huntington's disease: Studies with structural imaging techniques and positron emission tomography
109. Cerebral metabolism and atrophy in Huntington's disease determined by 18FDG and computed tomographic scan
110. Cerebral glucose consumption measured by PET in patients with and without psychiatric symptoms of Huntingdon's disease
111. Cerebral metabolic decline. A biochemical marker of genetic expression in Huntington's disease
112. Reduced cerebral glucose metabolism in asymptomatic patients at risk for Huntington's disease
113. PET and movement disorders
114. Positron emission tomography in the early diagnosis of Huntington's disease
115. Motor and cognitive improvements in patients with Huntington's disease after neural transplantation
116. Corticsal and subcortical glucose consumption measured by PET in patients with Huntington's disease
117. PET scan investigations of Huntington's disease. Cerebral metabolic correlates of neurological features and functional decline
118. Positron emission tomographic scan investigations of Huntington's disease. Cerebral metabolic correlates of cognitive function
119. On the influence of spatial resolution and of the size and form of regions of interest on the measurement of regional cerebral metabolic rates by positron emission tomography
120. Studies in persons at risk for Huntington's disease
121. The combined use of positron emission tomography and DNA polymorphisms for preclinical detection of Huntington's disease
122. Normal caudate glucose metabolism in persons at risk for Huntington's disease
123. Positron emission tomographic studies of regional cerebral glucose metabolism in idiopathic dystonia
124. Cerebral metabolic activity in idiopathic dystonia studied with positron emission tomography
125. PET studies of cerebral glucose metabolism in idiopathic torticollis
126. Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography
127. Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy
128. Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy
129. Atrophy of the corpus callosum, cognitive impairment, and cortical hypometabolism in progressive supranuclear palsy
130. Cerebral oxygen metabolism in patients with progressive supranuclear palsy: A positron emission tomography study
131. Steel-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow, and fluorodopa uptake measured by positron emission tomography
132. Epileptic patterns of local cerebral metabolism and perfusion in humans determined by emission computed tomography of 18FDG and 13NH3
133. Positron emission tomography studies of cerebral glucose metabolism in chronic partial epilepsy
134. Pathologic findings underlying focal temporal lobe hypometabolism in partial epilepsy
135. Comparative localization of the epileptic foci in partial epilepsy by PCT and EEG
136. Local cerebral metabolism during partial seizures
137. The role of positron emission tomography in the evaluation of seizure disorders
138. 18F-fluorodeoxyglucose positron emission tomography in refractory complex partial seizures
139. Interictal cerebral metabolism in partial epilepsies of neocortical origin
140. PET scanning in partial epilepsy
141. Epilepsy, cerebral blood flow, and cerebral metabolic rate
142. Neuroimaging for investigation of seizures in children
143. Effects of duration of epilepsy on the uncoupling of metabolism and blood flow in complex partial seizures
144. Relationship of seizure frequency to hippocampus volume and metabolism in temporal lobe epilepsy
145. Pattern of interictal hypometabolism in PET scans with fludeoxyglucose F 18 reflects prior seizures types in patients with mesial temporal lobe seizures
146. Contributions of positron emission tomography to understanding mechanisms of epilepsy
147. Pathology of temporal lobe foci: Correlation with CT, MRI and PET
148. Positron emission tomographic measurement of cerebral blood flow and temporal lobectomy
149. Predictors of outcome after anterior temporal lobectomy: Positron emission tomography
150. Temporal lobe hypometabolism on PET: Predictor of seizure control after temporal lobectomy
151. Outcome of temporal lobe epilepsy surgery predicted by statistical parametric PET imaging
152. Temporal lobectomy for uncontrolled seizures: The role of positron tomography
153. Postsurgical outcome of patients with uncontrolled complex partial seizures and temporal lobe hypometabolism on 18FDG-positron emission tomography
154. The value of PET scan (and MRI and Wada test) in patients with bitemporal epileptiform abnormalities
155. Neuroimaging in temporal lobe epilepsy: Test sensitivity and relationships to pathology and postoperative outcome
156. Thalamic metabolic asymmetry on FDG PET scans as a determinant of seizure outcome after temporal lobectomy
157. Long-term follow-up after cerebral hemispheroctomy. Neurophysiologic, radiologic, and psychological findings
158. Cerebral metabolism of the remote area after epilepsy surgery
159. Patterns of human local cerebral glucose metabolism during epileptic seizures
160. The use of PET scanning in epilepsy
161. Patterns of cerebral glucose metabolism in patients with partial seizures
162. Comparative study of interictal PET and ictal SPECT in complex partial seizures
163. FDG PET and MRI in temporal lobe epilepsy: Relationship to febrile seizures hippocampal sclerosis and outcome
164. Presurgical multimodality neuroimaging in electroencephalographic lateralized temporal lobe epilepsy
165. An interictal study of partial epilepsy using positron emission tomography and oxygen-15 inhalation method
166. Contribution of positron emission tomography to the investigation of epilepsies of frontal lobe origin
167. Correlations between the positron emission tomography measurement of glucose metabolism and oxygen utilization in focal epilepsy
168. Magnetic resonance imaging in intractable partial epilepsy: Correlative studies
169. Cerebral metabolic topography in unilateral temporal lobe epilepsy
170. Statistical parametric mapping of regional glucose metabolism in mesial temporal lobe epilepsy
171. Localization of epileptic foci
172. Preoperative EEG investigation in patients with frontal lobe epilepsy: Trends, results and pathophysiological considerations
173. Extracranial EEG evaluations
174. Surgery of frontal lobe epilepsy
175. Contribution of positron emission tomography to the investigation of epilepsies of frontal lobe origin
176. Histopathology of nonneoplastic lesions in frontal lobe epilepsy: Review of 180 cases with recent MRI and PET correlations
177. Studies of central nervous system disorders with single photon emission computed tomography and positron emission tomography. Evolution over the past 2 decades
178. Ictal patterns of cerebral glucose utilization in children with epilepsy
179. Effect of seizures on cerebral blood flow measured with 15O-H 2O and positron emission tomography
180. Infantile spasms. I. PET identifies focal cortical dysgenesis in cryptogenic cases for surgical treatment
181. Childhood epilepsy. Anatomical and functional neuroimaging
182. The use of positron emission tomography in the clinical assessment of epilepsy
183. Infantile spasms. II. Lenticular nuclei and brain stem activation on positron emission tomography
184. Lennox-Gastaut syndrome. Metabolic subtypes determined by 18-FDG positron emission tomography
185. Cerebral glucose metabolism in the Lennox-Gastaut syndrome
186. A case of Lennox-Gastaut syndrome successfully treated by removal of a parietotemporal astrocytoma
187. Hemispherectomy for Sturge-Weber syndrome
188. Sturge-Weber syndrome: A study of cerebral glucose utilization with positron emission tomography
189. Computerized tomography, magnetic resonance imaging, and positron emission tomography in the study of brain trauma. Preliminary observations
190. Positron emission tomography in the evaluation of head injury
191. Metabolic (PET) correlates of anatomic lesions (CT/MRI) produced by head trauma
192. Functional and anatomic studies of head injury
193. F-18 PET evaluation of crossed cerebellar diaschisis in head injury
194. Selected cases of poor outcome following minor brain trauma: Comparing neuropsychological and positron emission tomography assessment
195. Dissociation of cerebral glucose metabolism and level of consciousness during the period of metabolic depression following human traumatic brain injury
196. Cerebral hyperglycolysis following severe traumatic brain injury in humans: A positron emission tomography study
197. Use of PET methods for measurement of cerebral energy metabolism and hemodynamics in cerebrovascular disease
198. Noninvasive measurement of blood flow, oxygen consumption and glucose utilization in the same brain regions in man by positron emission tomography. Concise communication
199. Positron tomography in ischemia cerebrovascular disease
200. Use of PET to evaluate acute stroke and other cerebrovascular disorders
201. The clinical role of PET in cerebrovascular disease
202. Metabolic and clinical correlates of acute ischemic infarction
203. Positron imaging in is-chemic stroke disease using compound labeled with oxygen-15
204. Noninvasive tomographs study of cerebral blood flow and oxygen metabolism in vivo
205. Local CBF, oxygen extraction fraction (OEF) and CMRO2. Prognostic value in recent supratentorial infarction in humans
206. Cerebral oxygen metabolism and blood flow in human cerebral ischemic infarction
207. Effects of stroke on local cerebral metabolism and perfusion. Mapping by emission tomography of 18FDG and 12NH3
208. Cerebral blood flow and oxygen metabolism in patients with vascular dementia of the Binswanger type
209. Diaschisis
210. Contralateral cerebellar hypometabolism following cerebral insult. A positron emission tomographics study
211. Focal and remote dysmetabolism in stroke
212. Crossed cerebellar diaschisis. Further studies
213. Regional cerebral blood flow in leukoaraiosis and artherosclerotic carotid disease
214. Physiological response to focal cerebral ischemia in humans
215. Delayed intrahemispheric remote hypometabolism. Correlations with early recovery after stroke
216. Crossed cerebellar disaschisis in human supratentorial brain infarction
217. Crossed cerebellar diachisis. A remote functional depression secondary to supratentorial infarction in man
218. Crossed cerebellar diaschisis after middle cerebral artery infection
219. Positron emission tomography in cerebrovascular disorders
220. Cerebral glucose metabolism as a predictor of recovery from aphasia in ischemic stroke
221. Positron emission tomography measurements of cerebral blood flow and metabolism. How can they be used to study functional recovery from stroke? (An American perspective)
222. Can positron emission tomography be used to gauge the brain's capacity for functional recovery following stroke?
223. Long-term prognosis of poststroke aphasia studied with positron emission tomography
224. Neural correlates of recovery from aphasia after damage to left inferior frontal cortex
225. Tissue at risk of infarction rescued by early reperfusion: A positron emission tomography study in systemic recombinant tissue plasminogen activator thrombolysis of acute stroke
226. Quantitative neuroimaging for the evaluation of the effect of stroke treatment
227. Metabolic imaging of human brain tumors
228. Positron emission tomography using (18F) fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool
229. SPECT and PET imaging of brain tumors
230. Metabolic brain imaging correlated with clinical features and brain tumors
231. Positron emission tomography in patients with glioma. A predictor of prognosis
232. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET
233. Can the standardized uptake value characterize primary brain tumors on FDG-PET?
234. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodexyglucose and/or carbon-11-methionine
235. Neuroimaging of juvenile pilocytic astrocytomas: An enigma
236. Positron emission tomographic study of suppression of gray matter glucose utilization by brain tumors
237. Depressed cerebellar glucose metabolism in supratentorial tumors
238. Crossed cerebellar diaschisis and brain tumor biochemistry studied with positron emission tomography, [18F]fluorodeoxyglucose and [11C]methionine
239. Contralateral cortical diaschisis in a patient with cerebellar astrocytoma after radiation therapy
240. Clinical application of PET for the evaluation of brain tumors
241. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma
242. Prediction of survival in glioma patients by means of positron emission tomography
243. Uncoupling of hexose transport and phosphorylation in human gliomas demonstrated by PET
244. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors. PET and neuropathologic studies
245. Differentiation of cerebral radiation necrosis from tumor recurrence by (18F)FDG and 82Rb positron emission tomography
246. Changes in glucose uptake by malignant gliomas: Preliminary study of prognostic significance
247. Work in progress: (18F) fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain
248. Positron emission tomography of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome
249. Differentiating recurrent tumor from radiation necrosis: Time for reevaluation of positron emission tomography?
250. The use of PET in evaluating patients with primary brain tumors: Is it useful?
251. Reduced cerebral glucose metabolism and increased brain capillary permeability following high-dose methotrexate chemotherapy: A positron emission tomography study
252. "Eight-Drugs-In-One-Day" chemotherapy administered before and after radiotherapy to adult patients with malignant glioma
253. Eight-Drugs-In-One-Day chemotherapy in postirradiated adult patients with malignant gliomas
254. Changes of cerebral blood flow and oxygen and glucose metabolism following radiochemotherapy of gliomas. A PET study
255. Acute effect of carmustine on glucose metabolism in brain and glioblastoma
256. Cerebral metabolic change in patients with AIDS: Report of a six-month follow-up using positron-emission tomography
257. Cerebral metabolic dysfunction in AIDS: Findings in a sample with and without dementia
258. Differentiation of central nervous system lesions in AIDS patients using positron emission tomography (PET)
259. Brain imaging in acquired immunodeficiency syndrome dementia complex
260. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS
261. PET scanning and the human immunodeficiency virus-positive patient
262. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET
263. Positron emission tomographic study of affective disorders. Problems and strategies
264. Regional cerebral glucose metabolism in late life depression and Alzheimer's disease: A preliminary positron emission tomography study
265. Subgenual prefrontal cortex abnormalities in mood disorders
266. Brain glucose metabolism during non-rapid eye movement sleep in major depression. A positron emission tomography study
267. Regional cerebral metabolism associated with anxiety symptoms in affective disorder patients
268. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine
269. Regional metabolic effects of fluoxetine in major depression: Serial changes and relationship to clinical response
270. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulated and medial prefrontal cortex
271. Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression
272. Cerebral metabolic rates for glucose in mood disorders
273. The differential diagnosis of depression. Relevance of positron emission tomography studies of cerebral glucose metabolism to the bipolar-unipolar dichotomy
274. Positron emission tomography assessment of effects of benzodiazepines on regional glucose metabolic rate in patients with anxiety disorder
275. Neuroimaging and affective disorder in late life: A review
276. PET scanning and schizophrenia - What progress?
277. The current status of PET scanning with respect to schizophrenia
278. Structural and functional brain imaging in schizophrenia
279. Regional neural dysfunctions in chronic schizophrenia studied with positron emission tomography
280. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia
281. Hypofrontality in schizophrenia: Distributed dysfunctional circuits in neuroleptic-naive patients
282. Regional brain function in schizophrenia I. A positron emission tomography study
283. Positron emission tomographic scanning in predominantly never-treated acute schizophrenic patients
284. Altered relationships between metabolic rates of glucose in brain regions of schizophrenic patients
285. Regional brain glucose metabolism in drug-free schizophrenic patients and clinical correlates
286. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia
287. Pathophysiology of 'positive' thought disorder in schizophrenia
288. The deficit syndrome. Functional and structural characteristics
289. Cerebral metabolic activity correlates of subsyndromes in chronic schizophrenia
290. Prefrontal cortex activity in people with schizophrenia and control subjects. Evidence from positron emission tomography for remission of 'hypofrontality' with recovery from acute schizophrenia
291. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics
292. Decreased anterior cingulate gyrus metabolic rate in schizophrenia
293. Left globus pallidus abnormality in never-medicated patients with schizophrenia
294. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum
295. PET and MRI of the thalamus in never-medicated patients with schizophrenia
296. Cerebral blood flow and mental processes in schizophrenia
297. Patterns of cerebral blood flow in schizophrenia
298. Correlational patterns of cerebral glucose metabolism in never-medicated schizophrenics
299. Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients
300. Laterality in functional brain imaging studies of schizophrenia
301. Regional brain function in schizophrenia. II. Repeated evaluation with positron emission tomography
302. Laterality and frontality of cerebral blood flow and metabolism in schizophrenia. Relationship to symptom specificity
303. From syndrome to illness. Delineating the pathophysiology of schizophrenia with PET
304. Dysfunction in a prefrontal substrate of sustained attention in schizophrenia
305. Increased temporal lobe glucose use in chronic schizophrenic patients
306. MRI-SPECT and PET-EEG findings on brain dysfunction in schizophrenia
307. Glucose metabolic correlates of continuous performance test performance in adults with a history of infantile autism, schizophrenics, and controls
308. Anterior cingulate gyrus dysfunction and selective attention deficits in schizophrenia: [15O]H2O PET study during single-trial Stroop task performance
309. Altered hemispheric functional dominance during word generation in negative schizophrenia
310. Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia
311. Recalling word lists reveals "cognitive dysmetria" in schizophrenia: A positron emission tomography study
312. Functional imaging of memory retrieval in deficit vs nondeficit schizophrenia
313. Functional hypofrontality and working memory dysfunction in schizophrenia
314. Brain interactions in chronic schizophrenics under resting and activation conditions
315. Schizophrenia and cognitive dysmetria: A positron-emission tomography study of dysfunctional prefrontal-thalamic-cerebellar circuitry
316. Working memory control in patients with schizophrenia: A PET study during a random number generation task
317. Impaired recruitment of the hippocampus during conscious recollection in schizophrenia
318. Brain activations in schizophrenia during a graded memory task studied with functional neuroimaging
319. Frontotemporal cerebral blood flow change during executive and declarative memory tasks in schizophrenia: A positron emission tomography study
320. Brain metabolism in patients with schizophrenia before and after acute neuroleptic administration
321. Positron emission tomography and subcortical glucose metabolism in schizophrenia
322. Striatal metabolic rate and clinical response to neuroleptics in schizophenia
323. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients
324. Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder
325. Cerebral glucose metabolic rates in obsessive compulsive disorder
326. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder
327. Local cerebral glucose utilization in chronic alcoholics, a positron tomography study
328. Alterations in regional cerebral glucose metabolic rate in non-Korsakoff chronic alcoholism
329. Positron emission tomography determination of regional cerebral glucose metabolism in alcohol-dependent men and healthy controls using 11C-glucose
330. Neuropsychiatric disorders. Investigation of schizophrenia and substance abuse
331. Regional cerebral metabolism in female alcoholics of moderate severity does not differ from that of controls
332. Cerebellar hypometabolism in alcoholic cerebellar degeneration studied with FDG and PET
333. Decreased cerebral response to inhibitory neurotransmission in alcoholics
334. Effects of abstinence and relapse upon neuropsychological function and cerebral glucose metabolism in severe chronic alcoholism
335. Recovery of brain glucose metabolism in detoxified alcoholics
336. Acute effects of ethanol on regional brain glucose metabolism and transport
337. The pharmacology of cocaine related to its abuse
338. Brain imaging studies of cocaine abuse: Implications for medication development
339. Cocaine-induced reduction of glucose utilization in human brain. A study using positron emission tomography and [fluorine 18]-fluorodeoxyglucose
340. Long-term frontal brain metabolic changes in cocaine abusers
341. Changes in brain glucose metabolism in cocaine dependence and withdrawal